Fli1 and Tissue Fibrosis in Various Diseases.
Elena V MikhailovaIrina V RomanovaAlexei Y BagrovNatalia I AgalakovaPublished in: International journal of molecular sciences (2023)
Being initially described as a factor of virally-induced leukemias, Fli1 (Friend leukemia integration 1) has attracted considerable interest lately due to its role in both healthy physiology and a variety of pathological conditions. Over the past few years, Fli1 has been found to be one of the crucial regulators of normal hematopoiesis, vasculogenesis, and immune response. However, abnormal expression of Fli1 due to genetic predisposition, epigenetic reprogramming (modifications), or environmental factors is associated with a few diseases of different etiology. Fli1 hyperexpression leads to malignant transformation of cells and progression of cancers such as Ewing's sarcoma. Deficiency in Fli1 is implicated in the development of systemic sclerosis and hypertensive disorders, which are often accompanied by pronounced fibrosis in different organs. This review summarizes the initial findings and the most recent advances in defining the role of Fli1 in diseases of different origin with emphasis on its pro-fibrotic potential.
Keyphrases
- systemic sclerosis
- immune response
- interstitial lung disease
- induced apoptosis
- dna methylation
- gene expression
- poor prognosis
- bone marrow
- acute myeloid leukemia
- signaling pathway
- cell cycle arrest
- transcription factor
- high glucose
- endothelial cells
- cell death
- drug induced
- anti inflammatory
- liver fibrosis
- binding protein